**Company Profile**

**Industry Sector:** Biotech Vaccine Discovery and Development

**Company Overview:** We use our proprietary virus-like particle (VLP) technology platform to discover highly active, yet safe, vaccines and then perform initial development. **Successful pre-clinical milestones** have been achieved with several pandemic influenza candidates (H5N1, H7N7, H1N1-1918) and we aim to initiate human clinical trials by year-end 2010.

The technology was invented by Dr. Galarza while a Principal Scientist at Wyeth. The company was founded in 2004 by Dr. J. Galarza based on a license from Wyeth with co-exclusivity on certain indications. TechnoVax benefits from over $5 million invested in the VLP technology platform since 1996.

**Target Market(s):**
Annual vaccine sales worldwide are projected to reach **$18 billion** and to increase 12% per year.
- Large and medium sized players, within the **Pharmaceutical Industry**, active or looking to enter the infectious diseases market.
- **Regional and local markets** with no current vaccine production capabilities seeking to take control of their national demand and supply.

**Management**

**Leadership:**
- **Jose M. Galarza**, President and CEO. 27 years of academic and industrial experience in the fields of virology and vaccine development.
- **George Martin**, Chief Technical Officer. Scientist Emeritus at the National Institutes of Health and former Senior Vice President for Scientific Affairs of Fibrogen, Inc.

**Scientific Advisory Board:**
- **Doris Bucher**, PhD, Professor Dept. of Microbiology and Immunology, New York Medical College.
- **Nathan Litman**, MD, Professor of Pediatrics, Albert Einstein College of Medicine, and Director of Pediatrics and Pediatric Infectious Diseases, Children’s Hospital at Montefiore.
- **Raphael P. Viscidi**, MD, Professor of Pediatrics at Johns Hopkins University School of Medicine.
- **Stephen Udem**, MD, PhD, internationally recognized virologist and vaccinologist and former Vice President of Wyeth vaccine division.

**Key Value Drivers**

**Technology:** TechnoVax has developed a novel way to produce highly immunogenic, non-infectious monovalent and polyvalent virus-like particle vaccines using a cell-based manufacturing system requiring no chemical inactivation. The technology is used to produce mass market vaccines for infectious diseases including influenza, respiratory syncytial virus (RSV), para-influenza virus (PIV) and other diseases such as Dengue, HIV and cancer.

**Competitive Advantage:** TechnoVax’s novel polyvalent VLP vaccines are produced in a high yield single manufacturing step utilizing a new, low investment, manufacturing process, reducing manufacturing time, steps and costs.

**Plan & Strategy:** Actively seeking **strategic partners** in our **target markets:**
- At regional level;
- Product centered;
- Project oriented;

We plan to develop and commercialize **safe and efficacious novel vaccines** with the most time and cost-effective manufacturing technology in order to unlock significant commercial and competitive advantages.

*Technology funded by the NIH grants and being commercialized under the NIH-CAP*

**Product Pipeline and IP**

<table>
<thead>
<tr>
<th>Discovery</th>
<th>Pre-clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>TVX001 – Seasonal Influenza</td>
<td>✔️ ✔️ ✔️</td>
<td>Q4-2010</td>
<td>Q3-2011</td>
<td>Q2-2012</td>
</tr>
<tr>
<td>TVX002 H1N1/ SW flu A</td>
<td>✔️ ✔️ ✔️</td>
<td>Q4-2010</td>
<td>Q3-2011</td>
<td>Q2-2012</td>
</tr>
<tr>
<td>TVX003 - H5N1</td>
<td>✔️ ✔️ ✔️</td>
<td>TBD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TVX004 H1N1 (1918)</td>
<td>✔️ ✔️ ✔️</td>
<td>TBD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TVX005 - H7N7</td>
<td>✔️ ✔️ ✔️</td>
<td>TBD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TVX006 Undisclosed Target</td>
<td>✔️ ✔️ ✔️</td>
<td>2010</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TVX007-11 Undisclosed Targets</td>
<td>✔️ ✔️ ✔️</td>
<td>TBD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Patented technology and licensed by Wyeth with the option to sub-licence.
- Co-exclusive license with Wyeth for other respiratory virus targets (RSV, PIV, etc.)
- Additional patent applications protect proprietary VLP production for RSV, HIV as well as manufacturing methods.